Amgen and Arrakis Therapeutics Announce Multi-Target …
THOUSAND OAKS, Calif. and WALTHAM, Mass., Jan. 11, 2022 – Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and …
News Releases - Arrakis Therapeutics
Jan 10, 2022 · Arrakis Therapeutics Enters Strategic Collaboration and License Agreement with Roche for Multi-Target Program Utilizing RNA-Targeted Small Molecule Drug Discovery Platform
Arrakis - Arrakis Therapeutics
Amgen and Arrakis Therapeutics Announce Multi-Target Collaboration to Identify Novel RNA Degrader Small Molecule Therapeutics
AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI …
Jan 11, 2022 · Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas.
Amid a pandemic, Roche bets $190M on Arrakis and drugging RNA
Apr 8, 2020 · Arrakis now has a pipeline that includes potential drugs for cancer, neurological diseases, rare disorders, and dyslipidemia. The Roche deal is the company's first, but it marks …
Drugging RNA - Nature Biotechnology
May 17, 2023 · Ribometrix is primarily targeting mature mRNAs, again unspecified. Arrakis has disclosed its lead program, which targets the mature mRNA encoding the myc transcription …
Arrakis Therapeutics to Present at Jefferies Healthcare Conference
Jun 1, 2022 · Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas.
Amgen partners with Arrakis to develop drugs aimed at RNA
Jan 11, 2022 · Amgen will team with Arrakis Therapeutics to develop oral drugs that target and destroy RNA, announcing a deal Tuesday that will pay the Waltham, Massachusetts-based …
Amgen, Arrakis partner to develop drugs that eliminate ... - STAT
Jan 11, 2022 · A mgen and the biotech startup Arrakis Therapeutics announced a research collaboration Tuesday to discover and develop a new class of oral drugs that selectively …
AMGEN AND ARRAKIS THERAPEUTICS ANNOUNCE MULTI …
Jan 11, 2022 · Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas.
- Some results have been removed